Erudio Healtherudio.com
Sponsor
Verastem trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Verastem yet. Erudio has found public clinician commentary on 6 clinical trials sponsored by Verastem, including RAMP 201, RAMP 203, RAMP 301 and TARGET-D 203. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Verastem, Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| RAMP 201 NCT04625270 · Verastem, Inc. DeepView → | recurrent low-grade serous ovarian cancer | Phase 2 | Deep | View | |||
| RAMP 301 NCT06072781 · Verastem, Inc. DeepView → | recurrent low-grade serous ovarian cancer | Phase 3 | Deep | View | |||
| RAMP 203 NCT05074810 · Verastem, Inc. FocusedView → | KRAS G12C mutant non-small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||
| TARGET-D 203 NCT07659795 · Verastem, Inc. FocusedView → | metastatic KRAS G12D-mutated colorectal adenocarcinoma | Phase 2 | Focused | View | |||
| RAMP202 NCT04620330 · Verastem, Inc. FocusedView → | recurrent KRAS-mutant or BRAF-mutant non-small cell lung cancer | Phase 2 | Focused | View | |||
| TARGET-D 201 NCT07644559 · Verastem, Inc. FocusedView → | Not given | Phase 2 | Focused | View | |||